Lawyer for Aviator LLC Details Origin of Aviator Logo Following Court Victory
4.9.2024 11:00:00 EEST | Business Wire | Press release
After winning an important $330 million infringement ruling by the Georgian Court of First Instance against Adjarabet and Spribe OÜ, and in response to statements published in the media by the defendants, Nikoloz Gogilidze, Managing Partner of the law firm Mikadze Gegetchkori Taktakishvili LLC which represents Aviator LLC, says that the Aviator brand (the name and the logo) was created in 2016-2017 by Georgian businessman Teimuraz Ugulava.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240904224604/en/
Left image: Original logo owned by Aviator LLC, used illegally in Georgia by Adjarabet and Spribe OÜ until January 2024. Right image: Modified logo used internationally by Spribe OÜ, invalidated by Aviator LLC in Georgia. (Graphic: Business Wire)
Mr. Gogilidze shares further history of the ownership of the brand, as detailed in submissions before the court:
In 2018, the “Aviator” trademark was duly registered with the Georgian State Trademark Agency (Sakpatenti; www.sakpatenti.gov.ge/en) by City Loft LLC, company solely owned by Teimuraz Ugulava. In 2018, Mr. Ugulava owned two gambling companies, the land casino Aviator and the online platform Adjarabet. The design of Aviator logo was initially used for the land casino Aviator. At the same time, Adjarabet, which was also owned by Ugulava, launched the crash game Aviator in collaboration with Spribe OÜ. As the creation of the game was financed by Adjarabet (while still under Termuraz Ugulava’s ownership), City Loft provided its bare consent for Adjarabet to use the same Aviator logo and airplane image.
Gogilidze says that Aviator crash game was launched on the Adjarabet online casino in January 2019, when the company was still 100% owned by Teimuraz Ugulava. Soon after launching the game, Adjarabet was sold to Flutter Entertainment Plc. None of the agreements executed with Flutter provided any rights to the Aviator trademarks. Moreover, the Agreement provided the list of trademarks transferred to the purchaser as a result of the share sale, which included the brand “Adjarabet”, also registered in the State Trademark Agency back at the time, but not the trademark “Aviator.”
Spribe OÜ and Adjarabet continued using the logo for the game on the Adjarabet platform in both the Georgian and Armenian markets until January 2024.
Gogilidze says that when Spribe OÜ decided to take the game outside Georgia, it deliberately made a slight modification to the logo and continued to use modified logo outside. At the same time, Spribe OÜ applied for registration of the modified logo in Georgia in 2022 and in the European Union in 2023.
As detailed in the court submissions, in 2022 all intellectual property related to the Aviator trademark and the airplane image was transferred from City Loft to Aviator LLC, a gaming company active in the land casino sector in Georgia. In order to protect its IP rights, Aviator LLC brought the invalidation action before the Georgian courts against, amongst others, Spribe OÜ.
For further information and media queries, please contact Aviator LLC’s representatives at info.aviator@mikadze.ge.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240904224604/en/
Contacts
Nikoloz Gogilidze, info.aviator@mikadze.ge
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 08:00:00 EEST | Press release
Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufacturing site. All other aspects of the BLA, including safety- and efficacy-related parts, did not solicit deficiencies to be addressed. The FDA made observations during the PLI for which Galderma is putting in place corrective and preventive actions. Galderma will also be seeking further guidance through continued open dialogue with the FDA toward resolution of the relevant observations. Galderma plans to rapidly respond to the CRL and advancing RelabotulinumtoxinA in the U.S. remains a top priority. The ob
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 04:45:00 EEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 02:56:00 EEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom